Market closed
Agenus/$AGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Agenus
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Ticker
$AGEN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
316
Website
Agenus Metrics
BasicAdvanced
$80M
-
-$10.59
1.48
-
Price and volume
Market cap
$80M
Beta
1.48
52-week high
$19.69
52-week low
$1.38
Average daily volume
690K
Financial strength
Current ratio
0.206
Quick ratio
0.184
Long term debt to equity
-27.785
Total debt to equity
-30.998
Interest coverage (TTM)
-1.03%
Management effectiveness
Return on assets (TTM)
-28.79%
Return on equity (TTM)
102.14%
Valuation
Price to revenue (TTM)
0.612
Price to book
-0.21
Price to tangible book (TTM)
-0.2
Price to free cash flow (TTM)
-0.399
Growth
Revenue change (TTM)
-33.81%
Earnings per share change (TTM)
-22.95%
3-year revenue growth (CAGR)
-29.53%
3-year earnings per share growth (CAGR)
71.25%
What the Analysts think about Agenus
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Agenus stock.
Agenus Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Agenus Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Agenus News
AllArticlesVideos
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
Business Wire·1 week ago
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
Business Wire·1 week ago
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Agenus stock?
Agenus (AGEN) has a market cap of $80M as of May 08, 2025.
What is the P/E ratio for Agenus stock?
The price to earnings (P/E) ratio for Agenus (AGEN) stock is 0 as of May 08, 2025.
Does Agenus stock pay dividends?
No, Agenus (AGEN) stock does not pay dividends to its shareholders as of May 08, 2025.
When is the next Agenus dividend payment date?
Agenus (AGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Agenus?
Agenus (AGEN) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.